The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 801–900 of 999
Hou, C. J., Zhou, L., Yang, M., Jiang, S., Shen, H., Zhu, M., Chen, J., Miao, M., Xu, Y., & Wu, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700234 · Cited by 11
Yabe, M., Omarbekova, A. Z., Hsu, M., May, H., Arcila, M. E., Liu, Y., Doǧan, A., Brunner, A. M., Nardi, V., Hasserjian, R. P., et al. (2021) · Cancers · doi:10.3390/cancers13215502 · Cited by 9
Merkerová, M. D., & Krejčík, Z. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5285 · Cited by 10
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice
García-Ruiz, C., Martínez-Valiente, C., Cordón, L., Liquori, A., Fernández‐González, R., Pericuesta, E., Sandoval, J., Cervera, J., Gutiérrez‐Adán, A., & Sanjuán-Pla, A. (2022) · Leukemia · doi:10.1038/s41375-022-01674-2 · Cited by 10
Liu, J., Min, S., Kim, D. C., Park, J., Park, E., Pei, S., Koh, Y., Shin, D., Byun, J. M., Ko, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01954-5 · Cited by 12
Early Splicing Complexes and Human Disease
Nagasawa, C. K., & García-Blanco, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411412 · Cited by 11
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms
Baranwal, A., Gurney, M. E., Basmaci, R., Katamesh, B., He, R. L., Viswanatha, D. S., Greipp, P. T., Foran, J. M., Badar, T., Murthy, H. S., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284185 · Cited by 10
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, N. D., Yu, X., Kuykendall, A. T., Moon, J., Su, S., Cheng, C., Sammut, R., Razabdouski, T. N., Nguyen, H. V., Eksioglu, E. A., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0210 · Cited by 10
RNA splicing as a therapeutic target in myelodysplastic syndromes
Tseng, C.-C., & Obeng, E. A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.005 · Cited by 11
Mukherjee, S., Boccaccio, D. E., Sekeres, M. A., & Copelan, E. A. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.027 · Cited by 11
Gao, L., Liu, F., Zhang, H., Sun, J., & Ma, Y.-G. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22322 · Cited by 10
Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron, E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.349 · Cited by 11
Current management of patients with chronic myelomonocytic leukemia
Piérola, A. A., Bravo, G. M., & Garcia‐Manero, G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000337 · Cited by 10
Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects
Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 10
The Progress of Next Generation Sequencing in Assessment of Myeloid Malinancies
Puyan, F. Ö., & Alkan, S. (2018) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2018.2018.1195 · Cited by 10
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Thol, F. R., & Platzbecker, U. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018022434 · Cited by 10
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Sanz, G. F., Ibáñez, M., & Such, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000680 · Cited by 11
Molecular/Cytogenetic Education for Hematopathology Fellows
Beck, R. C., Kim, A. S., Goswami, R. S., Weinberg, O. K., Yeung, C. C. S., & Ewalt, M. D. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa038 · Cited by 10
Chromatin Regulator SPEN/SHARP in X Inactivation and Disease
Giaimo, B. D., Robert-Finestra, T., Oswald, F., Gribnau, J. H., & Borggrefe, T. (2021) · Cancers · doi:10.3390/cancers13071665 · Cited by 12
Wang, S. A., Ok, C. Y., Kim, A. S., Lucas, F. M., Morgan, E. A., Thakral, B., Patel, S. S., Nardi, V., Patel, K., Weinberg, O. K., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26325 · Cited by 10
Is race important in genomic classification of hematological neoplasms?
Huang, H., Wu, J., Qin, T., Xu, Z., Qu, S., Pan, L., Cai, W., Liu, J., Wang, H., Sun, Q., et al. (2021) · Hematological Oncology · doi:10.1002/hon.2909 · Cited by 10
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Comont, T., Treiner, E., & Vergez, F. (2021) · Diagnostics · doi:10.3390/diagnostics11111982 · Cited by 10
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
Fontana, D., Gambacorti-Passerini, C. B., & Piazza, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756348 · Cited by 10
Skalska-Bugała, A., Starczak, M., Szukalski, Ł., Gawroński, M., Siomek, A., Szpotan, J., Wołowiec, A., Zarakowska, E., Szpila, A., Jachalska, A., et al. (2022) · Cells · doi:10.3390/cells11050888 · Cited by 10
Rozza, R., Janoš, P., Spinello, A., & Magistrato, A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2114452 · Cited by 10
Skrdlant, L. M., Stark, J. M., & Lin, R.-J. (2016) · BMC Molecular Biology · doi:10.1186/s12867-016-0071-y · Cited by 10
Ruppenthal, S., Kleiner, H., Nolte, F., Fabarius, A. C., Hofmann, W., Nowak, D., & Seifarth, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191734 · Cited by 11
Přibyl, M., Hubáčková, S., Moudrá, A., Vančurová, M., Polackova, H., Stopka, T., Jonasova, A. T., Bokorová, R., Fuchs, O., Stritesky, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12768 · Cited by 10
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9
Jain, T., Ware, A. D., Dalton, W. B., Paşca, S., Tsai, H., Gocke, C. D., Gondek, L. P., Xian, R. R., Borowitz, M. J., & Levis, M. J. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107345 · Cited by 9
TP53 Y220C mutations in patients with myeloid malignancies
Gener‐Ricos, G., Bewersdorf, J. P., Loghavi, S., Bataller, Á., Goldberg, A. D., Sasaki, K., Famulare, C. A., Takahashi, K., Issa, G. C., Borthakur, G. M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2363440 · Cited by 11
Inflammatory signaling in the pathogenesis of acute myeloid leukemia
Baumann, A., & Ellegast, J. M. (2025) · HemaSphere · doi:10.1002/hem3.70188 · Cited by 9
Chen, X., Shukla, M., & Choi, J. H. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06374-2 · Cited by 9
van Spronsen, M. F., Ossenkoppele, G. J., Westers, T. M., & van de Loosdrecht, A. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.004 · Cited by 9
The Wilms’ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis
Jiang, Y., Liu, L., Wang, J., Cao, Z., & Zhao, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.23671 · Cited by 9
Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies
Czegle, I., Gray, A. L., Wang, M., Liu, Y., Wang, J., & Wappler-Guzzetta, E. A. (2021) · Life · doi:10.3390/life11121351 · Cited by 10
Weiss, E. H., Walter, W., Meggendorfer, M., Baer, C. R., Haferlach, C., Haferlach, T., & Kern, W. (2022) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22057 · Cited by 10
Self-citationHussein, S. E., & Loghavi, S. (2022) · Cancers · doi:10.3390/cancers14225690 · Cited by 10
Pellagatti, A., & Boultwood, J. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101055 · Cited by 10
Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations
Nazha, A., & Sekeres, M. A. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062915-095637 · Cited by 9
The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders
Bejar, R. L., & Greenberg, P. L. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0010 · Cited by 9
DNA Methyltransferase Inhibitors in Myeloid Cancer
Ørskov, A. D., & Grønbæk, K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000282 · Cited by 8
Blood Relatives: Splicing Mechanisms underlying Erythropoiesis in Health and Disease
Reimer, K. A., & Neugebauer, K. M. (2018) · F1000Research · doi:10.12688/f1000research.15442.1 · Cited by 9
Pati, H., & Veetil, K. K. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01084-y · Cited by 9
Murakami, Y., Kimura, Y., Kawahara, A., Mitsuyasu, S., Miyake, H., Tohyama, K., Endo, Y., Yoshida, N., Imamura, Y., Watari, K., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26784 · Cited by 9
Recent advances in MDS mutation landscape: Splicing and signalling
Follo, M. Y., Pellagatti, A., Ratti, S., Ramazzotti, G., Faenza, I., Fiume, R., Mongiorgi, S., Suh, P., McCubrey, J. A., Manzoli, L., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100673 · Cited by 9
Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study
Shi, X., Yang, Y., Shang, S., Wu, S., Zhang, W., Peng, L., Huang, T., Zhang, R., Ren, R., Mi, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6207-y · Cited by 9
Shallis, R. M., & Zeidan, A. M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101132 · Cited by 10
Franke, G., Lückemeier, P., & Platzbecker, U. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.10.008 · Cited by 9
Kim, T., Yoo, J., Moon, H. W., Hur, K. J., Choi, J. B., Hong, S., Lee, J. Y., & Ha, U. (2020) · BMC Cancer · doi:10.1186/s12885-020-07684-6 · Cited by 9
EnvIRONmental Aspects in Myelodysplastic Syndrome
Petzer, V., Theurl, I., Weiß, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105202 · Cited by 10
Baba, Y., Saito, B., Shimada, S., Sasaki, Y., Fujiwara, S., Arai, N., Kawaguchi, Y., Kabasawa, N., Tsukamoto, H., Uto, Y., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03187-7 · Cited by 10
Douet‐Guilbert, N., Soubise, B., Bernard, D. G., & Troadec, M. (2022) · Diagnostics · doi:10.3390/diagnostics12071658 · Cited by 11
Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population
Kamphuis, P., van Bergen, M. G. J. M., van Zeventer, I. A., de Graaf, A. O., Dinmohamed, A. G., Salzbrunn, J. B., Schuringa, J. J., van der Reijden, B. A., Huls, G. A., & Jansen, J. H. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000821 · Cited by 10
Yuan, X., Howie, K. L., Sabzvar, M. K., Chinnaswamy, K., Stuckey, J. A., & Yang, C. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00537 · Cited by 9
DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes
Huang, N., Yang, S., Shi, W., Guo, J., Zhang, Z., He, Q., Wu, L., Li, X., & Xu, F. (2023) · iScience · doi:10.1016/j.isci.2023.106962 · Cited by 9
Silzle, T., Blum, S., Kasprzak, A., Nachtkamp, K., Rudelius, M., Hildebrandt, B., Götze, K. S. S., Gattermann, N., Lauseker, M., & Germing, U. (2023) · Cancers · doi:10.3390/cancers15143572 · Cited by 9
Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?
Porwit‐MacDonald, A. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0272-3 · Cited by 9
Gupta, R., Rahman, K., Rahman, K., Singh, M. K., Singh, M. K., Kumari, S., Kumari, S., Yadav, G., Yadav, G., Nityanand, S., et al. (2017) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.048 · Cited by 9
Treatments targeting MDS genetics: a fool’s errand?
Dezern, A. E. (2018) · Hematology · doi:10.1182/asheducation-2018.1.277 · Cited by 9
Jajosky, A. N., Havens, N. P., Sadri, N., Oduro, K. A., Moore, E. M., Beck, R. C., & Meyerson, H. J. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa255 · Cited by 9
Gaiti, F., Chamely, P., Hawkins, A. G., Cortés-López, M., Swett, A. D., Ganesan, S., Mouhieddine, T. H., Dai, X., Kluegel, L., Chen, C. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.08.495292 · Cited by 9
Verigou, E., Chatzilygeroudi, T., Lazaris, V., de Lastic, A.-L., & Symeonidis, A. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447001 · Cited by 8
Nonsense-mediated mRNA decay: a key regulatory system engaged in cancer
Pan, H., Wu, X., Hu, B., Xiong, H., Luo, Y., & Zhou, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02503-6 · Cited by 8
Chen, L., Bian, Y., Pronk, E., van Dijk, C., van Tienhoven, T. V. D., Hoogenboezem, R. M., Bindels, E. M., Bosch, D. A., Fazeli, S., de Graaf, A. O., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65802-z · Cited by 10
Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome
Hou, H.-A., Kuo, Y.-Y., Chou, W.-C., Chen, P., & Tien, H. (2014) · Leukemia · doi:10.1038/leu.2014.71 · Cited by 8
Tanaka, T. N., Ferrari, V., Tarke, A., Fields, H. F., Ferrari, L., Ferrari, F., McCarthy, C., Sanchez, A. P., Vitiello, A., Lane, T. A., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.11.003 · Cited by 8
Past, present and future in low-risk myelodysplastic syndrome
Toprak, S. K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.967900 · Cited by 9
Goes, J. V. C., Carvalho, L. G., de Oliveira, R. T. G., Melo, M. M. D. L., Novaes, L. A. C., Moreno, D. A., Gonçalves, P. G., Montefusco-Pereira, C. V., Pinheiro, R. F., & Ribeiro, H. L. (2022) · Cancers · doi:10.3390/cancers14194611 · Cited by 8
Ribosome profiling analysis reveals the roles of DDX41 in translational regulation
Tungalag, S., Shinriki, S., Hirayama, M., Nagamachi, A., Kanai, A., Inaba, T., & Matsui, H. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03558-2 · Cited by 8
Impact of IPSS-M implementation in real-life clinical practice
Zamanillo, I., Poza, M., Ayala, R. M., Rapado, I., Martínez‐López, J., & Cedena, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199023 · Cited by 8
Ma, J., Gu, Y., Wei, Y., Wang, X., Wang, P., Song, C., & Ge, Z. (2023) · Blood Science · doi:10.1097/bs9.0000000000000166 · Cited by 8
Zhang, X., Lancet, J. E., & Zhang, L. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1037756 · Cited by 8
Cao-Sy, L., Obara, N., Sakamoto, T., Kato, T., Hattori, K., Sakashita, S., Nannya, Y., Ogawa, S., Harada, H., Sakata‐Yanagimoto, M., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-018-02576-9 · Cited by 8
Self-citationWilde, L. R., Cooper, J. K., Wang, Z., & Liu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01016 · Cited by 8
Ferrari, V., Tarke, A., Fields, H. F., Ferrari, L., Conley, T., Ferrari, F., Koşaloğlu‐Yalçın, Z., Sette, A., Peters, B., McCarthy, C., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.10.003 · Cited by 9
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Kubasch, A. S., & Platzbecker, U. (2020) · Hematology · doi:10.1182/hematology.2020000126 · Cited by 8
Atlı, E. İ., Gürkan, H., Atli, E., Kırkızlar, H. O., Yalcintepe, S. A., Demır, S., Demirci, U., Eker, D., Mail, C., Kalkan, R., et al. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.013 · Cited by 8
Acha, P., Palomo, L., Fuster‐Tormo, F., Xicoy, B., Mallo, M., Manzanares, A., Grau, J., Marcé, S., Granada, I., Rodríguez‐Luaces, M., et al. (2021) · Cancers · doi:10.3390/cancers13040841 · Cited by 9
Liquori, A., Lesende‐Rodriguez, I., Palomo, L., Avetisyan, G., Ibáñez, M., González-Romero, E., Boluda-Navarro, M., Morote-Faubel, M., García-Ruiz, C., Martínez-Valiente, C., et al. (2021) · Cancers · doi:10.3390/cancers13081947 · Cited by 8
Tumor suppressors in acute myeloid leukemia
Wallwitz, J., Aigner, P., & Stoiber, D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1907372 · Cited by 9
Rosenthal, S. H., Gerasimova, A. V., Ma, C., Li, H.-R., Grupe, A., Chong, H. K., Acab, A., Smolgovsky, A., Owen, R. X., Elzinga, C. D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0243683 · Cited by 8
Splicing regulation in hematopoiesis
Chen, S., & Abdel-Wahab, O. I. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000661 · Cited by 9
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes
Mozessohn, L., Li, Q., Liu, N., Leber, B. F., Khalaf, D., Sabloff, M., Christou, G., Yee, K. W. L., Chodirker, L., Parmentier, A., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00668 · Cited by 8
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications
Malcovati, L., Ambaglio, I., & Elena, C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000229 · Cited by 8
Matsuo, M., Iwanaga, M., Kondo, H., Soda, M., Jo, T., Horio, K., Takasaki, Y., Kawaguchi, Y., Tsushima, H., Imaizumi, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.13025 · Cited by 8
Wang, J., Ai, X., Qin, T., Xu, Z., Zhang, Y., Liu, J., Li, B., Fang, L., Zhang, H., Pan, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13688 · Cited by 8
High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis
Kawabata, K. C., Hayashi, Y., Inoue, D., Meguro, H., Sakurai, H., Fukuyama, T., Tanaka, Y., Asada, S., Fukushima, T., Nagase, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.227 · Cited by 8
Self-citationIncorporating novel approaches in the management of MDS beyond conventional hypomethylating agents
Odenike, O. M. (2017) · Hematology · doi:10.1182/asheducation-2017.1.460 · Cited by 8
Ganguly, B. B., Mandal, S., Banerjee, N., Kadam, N. N., & Abbi, R. (2018) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2018.03.005 · Cited by 8
Stengel, A., Kern, W., Meggendorfer, M., Haferlach, T., & Haferlach, C. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1522439 · Cited by 8
Self-citationTargeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia
Wu, M., Guo, Z., Huang, G., & Ye, Y.-B. (2021) · Neoplasma · doi:10.4149/neo_2021_201230n1426 · Cited by 8
From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes
Gadji, M., & Pozzo, A. R. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22689 · Cited by 8
RNA binding protein‐directed control of leukemic stem cell evolution and function
Joshi, P., Chahi, A. K., Liu, L., Moreira, S., Vujovic, A., & Hope, K. J. (2024) · HemaSphere · doi:10.1002/hem3.116 · Cited by 9
Almaghrabi, R. O. M., Alyahyawi, Y., Keane, P., Mian, S. A., Habel, K., Atkinson, A., Ward, C., Bayley, R., Sargas, C., Menéndez, P. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60192-8 · Cited by 8
Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes
Wall, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6703-2_18 · Cited by 8
Fang, Y., Guo, J., Wu, D., Wu, L., Song, L., Zhang, Z., Zhao, Y., & Chang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610525 · Cited by 7
Sutandyo, N., Sari, R. M., Kosasih, A. S., Rinaldi, I., Louisa, M., Kevinsyah, A. P., & Winston, K. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.4.1107 · Cited by 7
Chien, Y.-C. C., Madarász, K., Csoma, S. L., Mótyán, J. A., Huang, H., Méhes, G., & Mokánszki, A. (2023) · Cancers · doi:10.3390/cancers15030898 · Cited by 6
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
